Follow-up evaluation of patients with liver test abnormalities detected during SARS-CoV2 infection.
COVID-19
SARS-CoV2
follow-up
liver function tests
metabolic-associated fatty liver disease (MAFLD)
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
31
05
2022
received:
10
03
2022
accepted:
07
06
2022
pubmed:
17
6
2022
medline:
12
8
2022
entrez:
16
6
2022
Statut:
ppublish
Résumé
Abnormal liver function tests (A-LFTs) during admission for coronavirus disease-19 (COVID-19) are frequent, but its evolution after COVID-19 resolution remains unexplored. We evaluated factors related to A-LFTs during COVID-19 and assessed the liver outcome after patients' discharge. This is a observational study including: (1) retrospective analysis of variables related to A-LFTs during COVID-19; and (2) follow-up evaluation with blood test, transient elastography and liver biopsy in those with persistent A-LFTs. A-LFTs were defined according to CTCAEv4.0. Among 595 patients, 366 (61.5%) showed A-LFTs. The ratio of partial pressure of oxygen and inspired oxygen fraction (P/F) below 200, ferritin ≥1000 ng/mL, male gender and antibiotic and immunomodulatory treatments were related to A-LFTs. Follow-up evaluation was performed in 153 individuals. Persistent A-LFTs at follow-up was similar in patients with/without A-LFTs during admission (14.1% vs. 4.9%, p = 0.104). Fifteen (93%) and 58 (39%) patients with/without A-LFTs at follow-up showed metabolic fatty liver disease criteria (p < 0.001), which were histologically confirmed. In conclusion, A-LFTs during COVID-19 were related to infection severity. Abnormalities remitted at follow-up in >80% of patients, and no correlation between A-LFTs at admission and at follow-up was found. Most patients with A-LFTs at follow-up had non-invasive and histologically proven fatty liver disease.
Identifiants
pubmed: 35708160
doi: 10.1111/jvh.13718
pmc: PMC9350227
doi:
Substances chimiques
RNA, Viral
0
Oxygen
S88TT14065
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
823-834Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Hepatology. 2020 Aug;72(2):389-398
pubmed: 32359177
J Viral Hepat. 2022 Sep;29(9):823-834
pubmed: 35708160
Biomed Pharmacother. 2020 Nov;131:110678
pubmed: 32861070
Hepatology. 2012 Nov;56(5):1751-9
pubmed: 22707395
Semin Liver Dis. 2020 Aug;40(3):321-330
pubmed: 32886936
Pathogens. 2020 May 30;9(6):
pubmed: 32486188
J Hepatol. 2020 Oct;73(4):807-816
pubmed: 32437830
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Hepatology. 2020 Oct;72(4):1169-1176
pubmed: 32725890
Hepatology. 2020 Sep;72(3):807-817
pubmed: 32473607
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
Gastroenterology. 2020 Jul;159(1):53-61
pubmed: 32353371
J Hepatol. 2021 Sep;75(3):659-689
pubmed: 34166721
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Clin Gastroenterol Hepatol. 2021 Oct;19(10):2182-2191.e7
pubmed: 34004326
J Hepatol. 2020 Sep;73(3):566-574
pubmed: 32298767
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):667-678
pubmed: 32405603
Am J Clin Pathol. 2006 May;125(5):710-21
pubmed: 16707372
Gastroenterology. 2019 May;156(6):1717-1730
pubmed: 30689971
J Viral Hepat. 2015 Mar;22(3):297-306
pubmed: 25164560
Gastroenterology. 2020 Jul;159(1):320-334.e27
pubmed: 32407808
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
J Neuroimmune Pharmacol. 2020 Sep;15(3):359-386
pubmed: 32696264